We are live on ! Find out more
CKPT

Checkpoint Therapeutics

Delisted

CKPT was delisted on the 29th of May, 2025.

47 hedge funds and large institutions have $17.2M invested in Checkpoint Therapeutics in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 24 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 6

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

38% more call options, than puts

Call options by funds: $694K | Put options by funds: $503K

36% more capital invested

Capital invested by funds: $12.6M → $17.2M (+$4.6M)

4% more funds holding

Funds holding: 4547 (+2)

1.1% more ownership

Funds ownership: 16.26%17.36% (+1.1%)

Holders
47
Holders Change
+2
Holders Change %
+4.44%
% of All Funds
0.67%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
24
Reduced
6
Closed
4
Calls
$694K
Puts
$503K
Net Calls
+$191K
Net Calls Change
-$10K
Name Holding Trade Value Shares
Change
Change in
Stake
AC
1
Armistice Capital
New York
$8.7M +$3.18M +1,380,000 +55%
Vanguard Group
2
Vanguard Group
Pennsylvania
$3.08M +$86.1K +37,324 +3%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$958K +$288K +124,787 +41%
BlackRock
4
BlackRock
New York
$469K +$15.5K +6,723 +3%
PAM
5
PVG Asset Management
Colorado
$336K +$29.3K +12,676 +9%
Wealth Enhancement Advisory Services
6
Wealth Enhancement Advisory Services
Minnesota
$291K +$185K +80,000 +160%
Morgan Stanley
7
Morgan Stanley
New York
$232K +$215K +93,000 +873%
State Street
8
State Street
Massachusetts
$212K +$53.1K +23,000 +32%
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$206K +$71.5K +31,003 +51%
Renaissance Technologies
10
Renaissance Technologies
New York
$199K +$26.7K +11,590 +15%
D.E. Shaw & Co
11
D.E. Shaw & Co
New York
$198K +$98K +42,468 +92%
LWAM
12
Legacy Wealth Asset Management
Minnesota
$190K
Envestnet Asset Management
13
Envestnet Asset Management
Illinois
$187K +$639 +277 +0.3%
HWM
14
HB Wealth Management
Georgia
$175K +$180K +78,000 New
Walleye Capital
15
Walleye Capital
New York
$148K +$152K +65,948 New
Marshall Wace
16
Marshall Wace
United Kingdom
$140K +$145K +62,703 New
Northern Trust
17
Northern Trust
Illinois
$140K
Royal Bank of Canada
18
Royal Bank of Canada
Ontario, Canada
$136K +$1.2K +520 +0.9%
PAS
19
Park Avenue Securities
New York
$134K
CL
20
Choreo LLC
Illinois
$130K -$13.2K -5,725 -9%
LC
21
Lindbrook Capital
California
$112K +$11.5K +5,000 +11%
AI
22
Atria Investments
North Carolina
$107K -$28 -12 -0%
1WA
23
180 Wealth Advisors
Washington
$98.6K +$2.88K +1,250 +3%
Two Sigma Investments
24
Two Sigma Investments
New York
$94.1K +$47.1K +20,403 +94%
MFG
25
Magnus Financial Group
New York
$78.4K +$9.23K +4,000 +13%

CKPT Hedge Fund Activity: Q3 2024 in Review

47 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q3 2024, worth a combined $17.2M — up 36% from $12.6M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CKPT positions and 4 closed out — a net gain of 3 holders — while 24 added to existing stakes and 6 trimmed.

The largest buyer was Armistice Capital, adding an estimated $3.18M. The largest seller was B. Riley Wealth Advisors, exiting entirely with an estimated $493K sold.

  • 47 institutional investors held Checkpoint Therapeutics (CKPT) as of Q3 2024, up from 45 in Q2 2024.
  • Funds reported $17.2M of Checkpoint Therapeutics stock for Q3 2024, up 36% quarter-over-quarter.
  • 7 funds opened new Checkpoint Therapeutics positions in Q3 2024 and 4 closed out, a net change of +3 holders.
  • The largest Checkpoint Therapeutics buyer in Q3 2024 was Armistice Capital, an estimated $3.18M added.
  • The largest Checkpoint Therapeutics seller in Q3 2024 was B. Riley Wealth Advisors, an estimated $493K sold.

Based on aggregated 13F filings for Q3 2024.